Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904. https://doi.org/10.1016/j.jhep.2018.05.036.

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.

Article  PubMed  Google Scholar 

Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–700.

Article  PubMed  Google Scholar 

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691–705.

Article  CAS  PubMed  Google Scholar 

Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.

Article  Google Scholar 

Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

CAS  PubMed  Google Scholar 

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37(5):1202–1219. https://doi.org/10.1053/jhep.2003.50193.

Article  PubMed  Google Scholar 

Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):S47-64.

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.

Article  CAS  PubMed  Google Scholar 

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–90.

Article  PubMed  Google Scholar 

Eslam M, Ahmed A, Després J-P, Jha V, Halford JCG, Wei Chieh JT, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743–53.

Article  PubMed  Google Scholar 

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367.

Article  PubMed  Google Scholar 

Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–28.

Article  CAS  PubMed  Google Scholar 

Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–60.

Article  CAS  PubMed  Google Scholar 

Goff DCJ, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RBS, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25):2935–59.

Article  PubMed  Google Scholar 

Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet (London, England). 2013;382(9907):1762–5.

Article  Google Scholar 

Muntner P, Colantonio LD, Cushman M, Goff DCJ, Howard G, Howard VJ, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406–15.

Article  PubMed  PubMed Central  Google Scholar 

Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, et al. Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and European society of cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416–23.

Article  PubMed  Google Scholar 

DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular disease risk score in a modern mul. Eur Heart J. 2017;38(8):598–608.

CAS  PubMed  Google Scholar 

Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018;18(1):975. https://doi.org/10.1186/s12889-018-5806-x.

Article  PubMed  PubMed Central  Google Scholar 

Liang Y, Zhu C, Tian C, Lin Q, Li Z, Li Z, et al. Early prediction of ventilator-associated pneumonia in critical care patients: a machine learning model. BMC Pulm Med. 2022;22(1):250. https://doi.org/10.1186/s12890-022-02031-w.

Article  PubMed  PubMed Central  Google Scholar 

Lopez CD, Constant M, Anderson MJJ, Confino JE, Lanham NS, Jobin CM. Using machine learning methods to predict prolonged operative time in elective total shoulder arthroplasty. Semin Arthroplast JSES. 2022;32(3):452–61.

Article  Google Scholar 

Jin S, Qin D, Liang B-S, Zhang L-C, Wei X-X, Wang Y-J, et al. Machine learning predicts cancer-associated deep vein thrombosis using clinically available variables. Int J Med Inform. 2022;161:104733.

Article  PubMed  Google Scholar 

Lip GYH, Tran G, Genaidy A, Marroquin P, Estes C, Landsheft J. Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: comparing common clinical risk scores and machine learning algorithms. Eur Hear journal Qual care Clin outcomes. 2022;8(5):548–56.

Article  Google Scholar 

Kakadiaris IA, Vrigkas M, Yen AA, Kuznetsova T, Budoff M, Naghavi M. Machine learning outperforms ACC / AHA CVD risk calculator in MESA. J Am Heart Assoc. 2018;7(22): e009476.

Article  PubMed  PubMed Central  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Little RR. Glycated hemoglobin standardization–national glycohemoglobin standardization program (NGSP) perspective. Clin Chem Lab Med. 2003;41(9):1191–8.

Article  CAS  PubMed  Google Scholar 

Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002;48(2):236–54.

Article  CAS  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

Article  PubMed  PubMed Central  Google Scholar 

Xu W, Yu Q, Xie L, Chen B, Zhang L. Evaluation of Sysmex XN-1000 hematology analyzer for cell count and screening of malignant cells of serous cavity effusion. Medicine (Baltimore). 2017;96(27): e7433.

Article  CAS  Google Scholar 

Sişman AR, Küme T, Taş G, Akan P, Tuncel P. Comparison and evaluation of two C-reactive protein assays based on particle-enhanced immunoturbidimetry. J Clin Lab Anal. 2007;21(2):71–6.

Article  PubMed  PubMed Central  Google Scholar 

van Gammeren AJ, van Gool N, de Groot MJM, Cobbaert CM. Analytical performance evaluation of the Cobas 6000 analyzer - special emphasis on trueness verification. Clin Chem Lab Med. 2008;46(6):863–71.

PubMed  Google Scholar 

Dobriban E, Owen AB. Deterministic parallel analysis: an improved method for selecting factors and principal components. J R Stat Soc Ser B. 2019;81(1):163–83. https://doi.org/10.1111/rssb.12301.

Article  Google Scholar 

Unal I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Comput Math Methods Med. 2017;2017:3762651. https://doi.org/10.1155/2017/3762651.

Article  Google Scholar 

Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. Liver Int: official Journal of the International Association for the Study of the Liver. 2020;40:1016–7.

Article  Google Scholar 

Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018;2(4):376–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y-Y, Zhou X-D, Wu S-J, Fan D-H, Van PS, Chen Y-P, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun. 2018;2:376–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang Y, Ryu S, Sung K-C, Kyun Y, Sung E, Kim H-N, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung health study. Gut. 2019;68:1667–75.

Article  CAS  PubMed  Google Scholar 

Zhou Y-Y, Zhou X-D, Wu S-J, Hu X-Q, Tang B, van Poucke S, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(6):631–6.

Article  PubMed  Google Scholar